The Global Spinal Muscular Atrophy Treatment Market size is expected to reach $11.4 billion by 2028, rising at a market growth of 17.8% CAGR during the forecast period.
An extremely uncommon genetic condition called spinal muscular atrophy (SMA) damages the area of the central nervous system that regulates voluntary muscle movements. SMA is a neurological autosomal recessive genetic condition marked by muscular atrophy and deterioration. It is among the most prevalent genetic diseases with devastating symptoms and the main genetic cause of newborn mortality.
SMA is a genetic condition that runs in families. If the child has SMA, it is likely due to the presence of two faulty genes, one from each parent, in their body. Their system won't be capable of producing a particular form of protein as a result, the cells that govern muscles perish without it. If just one of the parents passes on a defective gene to the child, they will not develop SMA but they will be carriers of the condition.
The child might carry the damaged gene onto their offspring when they are adults. Depending on the type, spinal muscular atrophy symptoms might be very different. The most severe symptoms of Type 1 SMA in children are typically present during the initial six months of their lives and are more severe.
Those with milder kinds may not exhibit symptoms until the children are 18 months or older since they are less severe. Scoliosis, respiratory issues, swallowing and issues in feeding, delayed gross motor abilities, decreased muscle tone and muscle weakness, limited mobility, and delayed tongue motions are all possible signs of SMA.
Due to severe lockdown procedures and limited human movement, the COVID-19 pandemic has negatively impacted the spinal muscular atrophy treatment market. Since the majority of funding was used for COVID-19 vaccine production, the money obtained for Research and development activities and medication research for SMA was decreasing. Access to care for people with spinal muscular atrophy (SMA) was adversely affected by the pandemic. For instance, Cure SMA, a non-profit organization, voluntary-driven, dedicated solely to eliminating SMA, launched a poll in an attempt to assess the impact of the pandemic on the SMA community.
The prevalence and knowledge of spinal muscular atrophy have significantly increased, which is driving the demand for effective therapy options that improve patient outcomes. There have been two significant product introductions in the field of gene therapy recently. For a very long time, there was no cure for the rare condition spinal muscular atrophy, which frequently resulted in newborns and young children dying.
One of the major trends in spinal muscular atrophy (SMA) is expanding the opportunity for the reimbursement of costly medications globally in several countries. This is predicted to have a favorable impact on the uptake of costly gene therapies. France, Germany, Austria, and Italy are a few of the nations that have given all patients access to services that are reimbursed, and Israel and Hong Kong have done the same.
The high cost of treating rare genetic illnesses is one of the main factors that has constrained the expansion of the treatment facility. For instance, Spinraza is expected to cost US$ 708,000 in the first year and US$ 354,000 in each year after that, totaling US$ 3.9 million for the expense of treatment over a ten-year period. While a single Novartis therapy for Zolgensma is expected to cost US$ 2.1 million. By comparison, risdiplam can cost up to $340,000 annually. These expenses can undoubtedly cause serious problems for both patients and their families as well as healthcare professionals.
Based on type, the spinal muscular atrophy treatment market is categorized into type 1, type 2, type 3, and type 4. The Type 1 segment garnered the highest revenue share in the spinal muscular atrophy treatment market in 2021. The significant prevalence rate is responsible for this growth. About half of all newborn infants with SMA have this kind of SMA, making it more widespread. A number of treatments, notably Zolgensma (onasemnogene abeparvovec-xioi), have received FDA approval for the treatment of type-1 patients.
On the basis of treatment type, the spinal muscular atrophy treatment market is divided into gene therapy and drug. The drug segment acquired the largest revenue share in the spinal muscular atrophy treatment market in 2021. The segment is expanding because of the low cost of drug research and development as well as the simplicity of access relative to other treatments. Presently, three major FDA-approved drugs for the treatment of SMA are available on the market.
On the basis of route of administration, the spinal muscular atrophy treatment market is classified into oral and injection. The oral segment recorded a substantial revenue share in the spinal muscular atrophy treatment market in 2021. This is due to benefits like non-invasiveness, simplicity of pain avoidance, digestion, adaptability, and fewer side effects as opposed to other methods of administration methods that are linked with it.
| Report Attribute | Details |
|---|---|
| Market size value in 2021 | USD 3.7 Billion |
| Market size forecast in 2028 | USD 11.4 Billion |
| Base Year | 2021 |
| Historical Period | 2018 to 2020 |
| Forecast Period | 2022 to 2028 |
| Revenue Growth Rate | CAGR of 17.8% from 2022 to 2028 |
| Number of Pages | 252 |
| Number of Tables | 440 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling |
| Segments covered | Type, Route of Administration, Treatment Type, Region |
| Country scope | US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Australia, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria |
| Growth Drivers |
|
| Restraints |
|
Based on region, the spinal muscular atrophy treatment market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment procured the largest revenue share in the spinal muscular atrophy treatment market in 2021. The key drivers of the region's domination are the increasing incidence of SMA conditions and rising spending on treatment supplies. For instance, between 10,000 and 25,000 youngsters and adults reside in the United States who have SMA.
Free Valuable Insights: Global Spinal Muscular Atrophy Treatment Market size to reach USD 11.4 Billion by 2028
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biogen, Inc., Novartis AG, Ionis Pharmaceuticals, Inc., PTC Therapeutics, Inc., NMD Pharma A/S, Scholar Rock, Inc. (Scholar Rock Holding Corporation), Cytokinetics, Inc., Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.), Astellas Pharma, Inc., and F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
By Type
By Route of Administration
By Treatment Type
By Geography
The global Spinal Muscular Atrophy Treatment Market size is expected to reach $11.4 billion by 2028.
Growing R&D Activities For The Spinal Muscular Atrophy Treatment are driving the market in coming years, however, Extremely High Costs Of The Approved Products restraints the growth of the market.
Biogen, Inc., Novartis AG, Ionis Pharmaceuticals, Inc., PTC Therapeutics, Inc., NMD Pharma A/S, Scholar Rock, Inc. (Scholar Rock Holding Corporation), Cytokinetics, Inc., Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.), Astellas Pharma, Inc., and F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
The expected CAGR of the Spinal Muscular Atrophy Treatment Market is 17.8% from 2022 to 2028.
The Injection segment is leading the Global Spinal Muscular Atrophy Treatment Market by Route of Administration in 2021 thereby, achieving a market value of $8 billion by 2028.
The North America market dominated the Global Spinal Muscular Atrophy Treatment Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $5.9 billion by 2028.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 